Skip to NavigationSkip to content


Biogen signs $2 billion partnership deal with UPenn for gene therapies

Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to advance the development of gene therapy and gene editing technologies.

The partnership will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and central nervous system.

Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition

French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust Division and the Federal Trade Commission regarding its intention to acquire Medivation (Nasdaq: MDVN).  

Sanofi makes unsolicited $9.8 billion bid for Medivation

French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 billion in an all cash deal after the US drugmaker turned down the proposal. 

The company, looking to strengthen its prostate cancer portfolio, has offered Medivation $52.50 per share after the latter turned down deal talks early April. Sanofi followed up with a formal proposal on April 15.     

Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics Inc worth $75 million upfront  to jointly develop CRISPR/Cas gene-editing technology.

In addition, Regeneron will also invest up to $50 million in Intellia's next equity financing.

Pfizer to call off $160 billion merger with Allergan

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: AGN) according to reports, ending the biggest pharma deal as the US lawmakers take to enforcing stricter rules for corporations trying to dodge taxes.

The proposed regulations were announced on Monday by the Treasury Department with the aim to cut transactions that aid inversions for the corporates if there have been other similar deals over the past 36 months. For the same period, Allergan has had several similar acquisitions.

AstraZeneca completes respiratory deal with Almirall

Almirall image

AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million.

As reported by Pharmafile earlier in the year, the agreement will give AZ ownership of the rights for the development and commercialisation of Almirall’s respiratory business.

AZ, who originally announced the pact back in July, will also pay up to $1.22 billion in development, launch and sales-related milestones.

AstraZeneca shores up defences against Pfizer

Astrazeneca image

AstraZeneca has been making a series of big deals over the past three months as it looks to close the door once and for all on any Pfizer merger. 

AZ rebuffed Pfizer’s $118 billion offer for the firm in May for being too low, and its chief executive Pascal Soriot was clear that it intended to continue as an independent company.

AZ shareholders could have opened up talks with Pfizer this month to potentially accept a new bid, but have seemingly chosen not to go down this route.

Pfizer/AZ deal would put UK research in jeopardy

Pfizer image

The UK’s medical research collective has come together to warn the government that any deal between US giant Pfizer and Britain-based AstraZeneca, could have far-reaching consequences for R&D in the country.

The statement follows Pfizer’s announcement that it wants to buy AstraZeneca for $100 billion, which could see the firm sever much of AZ’s research base in the UK.

Pfizer makes second bid for AstraZeneca

Pfizer image

Pfizer has made a second attempt to buy AstraZeneca after an initial request was rejected in January.

The biggest pharma company in the world says in its first public statement on the issue that after ‘limited high-level discussions’ in January, AstraZeneca declined to pursue negotiations, causing Pfizer to back off.

Under fire Ranbaxy sold to Sun Pharma for $4 billion

Sun Pharma (pictured) and Ranbaxy will become India's biggest pharma fiirm

Sun Pharmaceutical Industries has bought struggling drugmaker Ranbaxy Laboratories in a deal that will see the two companies become the biggest in their native India.

Sun has agreed to acquire rival Ranbaxy – which is majority owned by Japan’s Daiichi Sankyo – an all-stock deal worth $4 billion (£2.4 billion)

Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches